drugset / Trial / NCT05467475

A Study in Healthy Men to Test How Esomeprazole Influences the Amount of BI 1819479 in the Blood

NCT05467475

Phase 1 Completed 15 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The main objective of this trial is to investigate the effect of the proton pump inhibitor esomeprazole on the pharmacokinetics of BI 1819479 in plasma.

Timeline

Start
2022-10-18
Primary completion
2023-01-23
Completion
2023-01-23

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1819479 Unknown Oral
Subject Esomeprazole Small molecule

Indications

No indication recorded.